Xin Lang Cai Jing·2025-08-25 07:39Core Viewpoint - The report from Zhongyin Securities indicates that Huadong Medicine's net profit attributable to shareholders for the first half of the year reached 1.815 billion yuan, representing a year-on-year growth of 7.01% [1] Business Segments Summary - The industrial segment of the company continues to grow rapidly, with its core subsidiary, China Medical Huadong, achieving revenue of 7.317 billion yuan (including CSO business), a year-on-year increase of 9.24%, and a net profit of 1.580 billion yuan, up 14.09% year-on-year [1] - The commercial segment reported revenue of 13.947 billion yuan in the first half, reflecting a year-on-year growth of 2.91%, with a net profit of 226 million yuan, an increase of 3.67% year-on-year [1] - The medical beauty segment faced external pressures from global macroeconomic fluctuations and market demand adjustments, resulting in a revenue of 1.112 billion yuan, showing a decline year-on-year [1] - The industrial microbiology segment achieved a total revenue of 368 million yuan, marking a year-on-year growth of 29% [1] - The company is optimistic about the future development prospects of its industrial segment as innovative products gradually enter the harvest period, and the commercialization team continues to expand and enhance the commercial network to ensure sustained growth of innovative products [1]